These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37800781)

  • 1. Clinical features and outcomes of Myasthenia Gravis associated with COVID-19 vaccines: A systematic review and pooled analysis.
    Tayebi AH; Samimisedeh P; Jafari Afshar E; Ayati A; Ghalehnovi E; Foroutani L; Abbasi Khoshsirat N; Rastad H
    Medicine (Baltimore); 2023 Oct; 102(40):e34890. PubMed ID: 37800781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuromuscular diseases associated with COVID-19 vaccines: a systematic review and pooled analysis of 258 patients.
    Tayebi A; Samimisedeh P; Jafari Afshar E; Mahmoudnia S; Milan N; Ayati A; Madady A; Rastad H
    BMC Neurol; 2023 Dec; 23(1):437. PubMed ID: 38082244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of mRNA COVID-19 vaccines in patients with well-controlled myasthenia gravis.
    Gamez J; Gamez A; Carmona F
    Muscle Nerve; 2022 Nov; 66(5):612-617. PubMed ID: 36029224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Clinical Course of New-Onset Ocular Myasthenia Gravis Caused by Pfizer-BioNTech COVID-19 Vaccine.
    Su WY; Lu CJ
    Acta Neurol Taiwan; 2023 Dec; 32(4)():218-222. PubMed ID: 37723915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective study on the safety of COVID-19 vaccination in myasthenia gravis.
    Urra Pincheira A; Alnajjar S; Katzberg H; Barnett C; Daniyal L; Rohan R; Bril V
    Muscle Nerve; 2022 Nov; 66(5):558-561. PubMed ID: 35673960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New-onset myasthenia gravis after mRNA SARS-CoV-2 vaccination: a case series.
    Fanella G; Baiata C; Candeloro E; Toscano G; Colnaghi S; Mauri M; Cariddi LP; Rebecchi V; Solazzo F; Banfi P; Piatti M; Ferrarese C; Versino M
    Neurol Sci; 2022 Oct; 43(10):5799-5802. PubMed ID: 35870026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An observational study on the safety of COVID-19 vaccination in patients with myasthenia gravis.
    Wang HY; Qiu L; Ou CY; Lin ZQ; Huang ZD; Chen P; Ma Q; Lu YR; Ran H; Liu WB
    Neurol Sci; 2023 Jul; 44(7):2239-2245. PubMed ID: 37160544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early-Onset Myasthenia Gravis Following COVID-19 Vaccination.
    Lee MA; Lee C; Park JH; Lee JH
    J Korean Med Sci; 2022 Mar; 37(10):e50. PubMed ID: 35289135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New-Onset Myasthenia Gravis Confirmed by Electrodiagnostic Studies After a Third Dose of SARS-CoV-2 mRNA-1273 Vaccine.
    Slavin E; Fitzig J; Neubert C; Garcia-Lopez F; Cuevas-Trisan R
    Am J Phys Med Rehabil; 2022 Dec; 101(12):e176-e179. PubMed ID: 35930797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cogan's sign in a patient with suspected post-COVID-19 vaccine-associated myasthenia gravis.
    Tavares-Júnior JWL; Sobreira-Neto MA; Braga-Neto P
    Rev Soc Bras Med Trop; 2023; 56():e0007. PubMed ID: 37283341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early safety and tolerability profile of the BNT162b2 COVID-19 vaccine in myasthenia gravis.
    Lotan I; Hellmann MA; Friedman Y; Stiebel-Kalish H; Steiner I; Wilf-Yarkoni A
    Neuromuscul Disord; 2022 Mar; 32(3):230-235. PubMed ID: 35227552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety of COVID-19 vaccines in patients with myasthenia gravis: A scoping review.
    Peng S; Tian Y; Meng L; Fang R; Chang W; Yang Y; Li S; Shen Q; Ni J; Zhu W
    Front Immunol; 2022; 13():1103020. PubMed ID: 36618419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocular myasthenia gravis in an academic neuro-ophthalmology clinic: clinical features and therapeutic response.
    Mittal MK; Barohn RJ; Pasnoor M; McVey A; Herbelin L; Whittaker T; Dimachkie M
    J Clin Neuromuscul Dis; 2011 Sep; 13(1):46-52. PubMed ID: 22361625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and tolerability of SARS-Cov-2 vaccination in patients with myasthenia gravis: A multicenter experience.
    Farina A; Falso S; Cornacchini S; Spagni G; Monte G; Mariottini A; Massacesi L; Barilaro A; Evoli A; Damato V
    Eur J Neurol; 2022 Aug; 29(8):2505-2510. PubMed ID: 35390184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 Vaccination and Late-Onset Myasthenia Gravis: A New Case Report and Review of the Literature.
    Virgilio E; Tondo G; Montabone C; Comi C
    Int J Environ Res Public Health; 2022 Dec; 20(1):. PubMed ID: 36612789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute onset ocular myasthenia gravis after vaccination with the Oxford-AstraZeneca COVID-19 vaccine.
    Maher DI; Hogarty D; Ben Artsi E
    Orbit; 2023 Dec; 42(6):630-634. PubMed ID: 35499172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of COVID-19 vaccine in patients with myasthenia gravis: a self-controlled case series study.
    Ruan Z; Huan X; Su Y; Tang YL; Meng DD; Ren DL; Li CH; Hao SJ; Zhao CB; Luo SS; Li ZY; Chang T
    Front Immunol; 2023; 14():1141983. PubMed ID: 37223097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between COVID-19 vaccination and myasthenia gravis: A population-based, nested case-control study.
    Arbel A; Bishara H; Barnett-Griness O; Cohen S; Najjar-Debbiny R; Gronich N; Auriel E; Saliba W
    Eur J Neurol; 2023 Dec; 30(12):3868-3876. PubMed ID: 37552795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of COVID-19 Infection and Vaccination Among Individuals With Myasthenia Gravis.
    Alcantara M; Koh M; Park AL; Bril V; Barnett C
    JAMA Netw Open; 2023 Apr; 6(4):e239834. PubMed ID: 37097637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. To Be or Not To Be Vaccinated: That Is a Question in Myasthenia Gravis.
    Zhou Q; Zhou R; Yang H; Yang H
    Front Immunol; 2021; 12():733418. PubMed ID: 34603311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.